Comparative Pharmacology
Head-to-head clinical analysis: RETEVMO versus SUNITINIB MALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RETEVMO versus SUNITINIB MALATE.
RETEVMO vs SUNITINIB MALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
Sunitinib is a multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase 3 (FLT3), colony-stimulating factor receptor type 1 (CSF-1R), and glial cell line-derived neurotrophic factor receptor (RET). It exerts antiangiogenic and antitumor activity by blocking signaling pathways involved in tumor growth and angiogenesis.
160 mg orally twice daily
50 mg orally once daily for 4 weeks, followed by 2 weeks off (4/2 schedule). Alternatively, 37.5 mg orally once daily on a continuous daily dosing schedule for gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor failure.
None Documented
None Documented
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
40-60 hours for sunitinib; 80-110 hours for active metabolite SU12662. Clinical context: supports once-daily dosing with 2 weeks on/1 week off schedule.
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Fecal (61%), renal (16%) as unchanged drug and metabolites.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor